콘텐츠로 건너뛰기
Merck
  • Intranasal flunisolide treatment in patients with non-allergic rhinitis.

Intranasal flunisolide treatment in patients with non-allergic rhinitis.

International journal of immunopathology and pharmacology (2011-06-11)
A Varricchio, M Capasso, A De Lucia, F Avvisati, A M Varricchio, G Bettoncelli, G Ciprandi
초록

Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation. Its treatment is still debated, intranasal corticosteroids may be an option. The present study is aimed at evaluating the effect of the use of intranasal flunisolide in patients with NAR, considering both clinical and cytological parameters. Sixty patients were treated with intranasal flunisolide (30) or saline solution (30) for 8 weeks. Symptom severity, turbinate size, and inflammatory cell counts were assessed, before and after treatment. Intranasal flunisolide induced a significant reduction of symptoms, turbinate size, and cellular infiltrate. Thus, intranasal flunisolide might be a therapeutic option for NAR.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Flunisolide, ≥97%